231 related articles for article (PubMed ID: 34512351)
1. Glycogen Metabolism Predicts the Efficacy of Immunotherapy for Urothelial Carcinoma.
Zhang Y; Li X; Zhou R; Lin A; Cao M; Lyu Q; Luo P; Zhang J
Front Pharmacol; 2021; 12():723066. PubMed ID: 34512351
[TBL] [Abstract][Full Text] [Related]
2. Development and validation of a genomic mutation signature to predict response to PD-1 inhibitors in non-squamous NSCLC: a multicohort study.
Bai X; Wu DH; Ma SC; Wang J; Tang XR; Kang S; Fu QJ; Cao CH; Luo HS; Chen YH; Zhu HB; Yan HH; Wu YL; Dong ZY
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32606052
[TBL] [Abstract][Full Text] [Related]
3. Predictive Value of the
Pan YH; Zhang JX; Chen X; Liu F; Cao JZ; Chen Y; Chen W; Luo JH
Front Immunol; 2021; 12():643282. PubMed ID: 34421886
[TBL] [Abstract][Full Text] [Related]
4. Identification and validation of a genomic mutation signature as a predictor for immunotherapy in NSCLC.
Wang Z; Ge Y; Li H; Fei G; Wang S; Wei P
Biosci Rep; 2022 Nov; 42(11):. PubMed ID: 36305643
[TBL] [Abstract][Full Text] [Related]
5. Characteristics of the Immune Cell Infiltration Landscape in Gastric Cancer to Assistant Immunotherapy.
Li C; Pan J; Jiang Y; Yu Y; Jin Z; Chen X
Front Genet; 2021; 12():793628. PubMed ID: 35069691
[No Abstract] [Full Text] [Related]
6. Molecular predictors of response to PD-1/PD-L1 inhibition in urothelial cancer.
Stühler V; Maas JM; Bochem J; da Costa IA; Todenhöfer T; Stenzl A; Bedke J
World J Urol; 2019 Sep; 37(9):1773-1784. PubMed ID: 30374610
[TBL] [Abstract][Full Text] [Related]
7. Hypoxic Characteristic Genes Predict Response to Immunotherapy for Urothelial Carcinoma.
Hong S; Zhang Y; Cao M; Lin A; Yang Q; Zhang J; Luo P; Guo L
Front Cell Dev Biol; 2021; 9():762478. PubMed ID: 34901008
[No Abstract] [Full Text] [Related]
8. Identification of an Immune-Related Risk Signature Correlates With Immunophenotype and Predicts Anti-PD-L1 Efficacy of Urothelial Cancer.
Li P; Hao S; Ye Y; Wei J; Tang Y; Tan L; Liao Z; Zhang M; Li J; Gui C; Xiao J; Huang Y; Chen X; Cao J; Luo J; Chen W
Front Cell Dev Biol; 2021; 9():646982. PubMed ID: 33816497
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcome after progressing to frontline and second-line Anti-PD-1/PD-L1 in advanced urothelial cancer.
Gómez de Liaño Lista A; van Dijk N; de Velasco Oria de Rueda G; Necchi A; Lavaud P; Morales-Barrera R; Alonso Gordoa T; Maroto P; Ravaud A; Durán I; Szabados B; Castellano D; Giannatempo P; Loriot Y; Carles J; Anguera Palacios G; Lefort F; Raggi D; Gross Goupil M; Powles T; Van der Heijden MS
Eur Urol; 2020 Feb; 77(2):269-276. PubMed ID: 31699525
[TBL] [Abstract][Full Text] [Related]
10. Activation of the chemokine receptor 3 pathway leads to a better response to immune checkpoint inhibitors in patients with metastatic urothelial carcinoma.
Feng W; Lin A; Sun L; Wei T; Ying H; Zhang J; Luo P; Zhu W
Cancer Cell Int; 2022 May; 22(1):186. PubMed ID: 35562800
[TBL] [Abstract][Full Text] [Related]
11. Immune Cell Infiltration Landscape of Ovarian Cancer to Identify Prognosis and Immunotherapy-Related Genes to Aid Immunotherapy.
Li X; Liang W; Zhao H; Jin Z; Shi G; Xie W; Wang H; Wu X
Front Cell Dev Biol; 2021; 9():749157. PubMed ID: 34805159
[TBL] [Abstract][Full Text] [Related]
12. Development and validation of a novel defined mutation classifier based on Lasso logistic regression for predicting the overall survival of immune checkpoint inhibitor therapy in renal cell carcinoma.
Chen M; Li P; Yao H; Liu F; Fu L; Wang Y; Zhu J; Xu Q; Liang H; Zhou Y; Wang Z; Deng Q; Chen W; Cao J; Chen X; Luo J
Transl Androl Urol; 2023 Mar; 12(3):406-424. PubMed ID: 37032757
[TBL] [Abstract][Full Text] [Related]
13. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
14. Multi-omics Perspective on the Tumor Microenvironment based on PD-L1 and CD8 T-Cell Infiltration in Urothelial Cancer.
Chen S; Zhang N; Shao J; Wang T; Wang X
J Cancer; 2019; 10(3):697-707. PubMed ID: 30719168
[No Abstract] [Full Text] [Related]
15. Identification of the Immune Cell Infiltration Landscape in Hepatocellular Carcinoma to Predict Prognosis and Guide Immunotherapy.
Yang S; Cheng Y; Wang X; Wei P; Wang H; Tan S
Front Genet; 2021; 12():777931. PubMed ID: 34899862
[No Abstract] [Full Text] [Related]
16. Association of MUC16 Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors.
Zhang L; Han X; Shi Y
JAMA Netw Open; 2020 Aug; 3(8):e2013201. PubMed ID: 32845327
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the Immune Cell Infiltration Landscape in Head and Neck Squamous Cell Carcinoma to Aid Immunotherapy.
Zhang X; Shi M; Chen T; Zhang B
Mol Ther Nucleic Acids; 2020 Dec; 22():298-309. PubMed ID: 33230435
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of PD-L1 expression on circulating tumor cells (CTCs) in patients with advanced urothelial carcinoma (UC).
Bergmann S; Coym A; Ott L; Soave A; Rink M; Janning M; Stoupiec M; Coith C; Peine S; von Amsberg G; Pantel K; Riethdorf S
Oncoimmunology; 2020; 9(1):1738798. PubMed ID: 32391189
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the Immune Cell Infiltration Profile in Pancreatic Carcinoma to Aid in Immunotherapy.
Luo D; Kuang F; Du J; Zhou M; Peng F; Gan Y; Fang C; Yang X; Li B; Su S
Front Oncol; 2021; 11():677609. PubMed ID: 34055645
[TBL] [Abstract][Full Text] [Related]
20. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
Manzano RG; Catalan-Latorre A; Brugarolas A
BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]